De­spite remde­sivir ap­proval and 2 big buy­outs, Gilead CEO Dan O'­Day sees pay fall 35% from 2019

For all in­tents and pur­pos­es, 2020 was a busy year for Gilead. The big biotech pulled off two big ac­qui­si­tions in Forty Sev­en and Im­munomedics, con­tin­ued see­ing growth in HIV prod­ucts de­spite ex­pir­ing patents on Tru­va­da and won the Covid-19 treat­ment race with a sharp piv­ot to remde­sivir ear­ly in the year, de­spite re­main­ing skep­ti­cism over the drug’s ef­fec­tive­ness.

In spite of all that, CEO Dan O’Day saw his com­pen­sa­tion fall dra­mat­i­cal­ly from 2019.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER